Toward a meningitis-free world

Science Translational Medicine

Volumn 4, Issue 123, 2012, Pages

  Black, Steven ^a   Pizza, Mariagrazia ^b   Nissum, Mikkel ^b   Rappuoli, Rino ^b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AC VAX; BEXSERO; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MENGIVAC; MENINGITIS VACCINE; MENINGOCOCCUS VACCINE; MENITORIX; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; UNCLASSIFIED DRUG;

AFRICA; ASYMPTOMATIC INFECTION; CLINICAL FEATURE; EPIDEMIC MENINGITIS; GEOGRAPHIC DISTRIBUTION; HUMAN; INCIDENCE; MASS IMMUNIZATION; MEDICAL HISTORY; MENINGITIS; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; REVIEW; SEPSIS; ARTICLE; CLASSIFICATION; DEVELOPING COUNTRY; DISEASE CONTROL; DRUG DESIGN; HEALTH; HEALTH CARE DELIVERY; IMMUNOLOGY; MICROBIOLOGY; ORGANIZATION; PATHOGENICITY; PUBLIC HEALTH;

CONGRESSES AS TOPIC; DEVELOPING COUNTRIES; DISEASE ERADICATION; DRUG DESIGN; HEALTH SERVICES ACCESSIBILITY; HUMANS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NATIONAL HEALTH PROGRAMS; NEISSERIA MENINGITIDIS; WORLD HEALTH;

EID: 84857761651     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003859     Document Type: Review

References (19)

1. A. R. Hinman, Global progress in infectious disease control. Vaccine 16, 1116-1121 (1998).
2. H. E. Hsu, K. A. Shutt, M. R. Moore, B. W. Beall, N. M. Bennett, A. S. Craig, M. M. Farley, J. H. Jorgensen, C. A. Lexau, S. Petit, A. Reingold, W. Schaff ner, A. Thomas, C. G. Whitney, L. H. Harrison, Eff ect of pneumococcal conjugate vaccine on pneumococcal meningitis. N. Engl. J. Med. 360, 244-256 (2009).
3. Scientific exchange meeting organized by Novartis, 2 and 3 July, 2011, Siena, Italy, "Towards a meningitis-free world. Can we eliminate meningococcal meningitis?"
4. D. S. Stephens, B. Greenwood, P. Brandtzaeg, Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 369, 2196-2210 (2007).
5. L. H. Harrison, Prospects for vaccine prevention of meningococcal infection. Clin. Microbiol. Rev. 19, 142-164 (2006).
6. N. E. Rosenstein, B. A. Perkins, D. S. Stephens, T. Popovic, J. M. Hughes, Meningococcal disease. N. Engl. J. Med. 344, 1378-1388 (2001).
7. Centers for Disease Control and Prevention (CDC), Factsheet: Meningococcal diseases and meningococcal vaccines (2009). http://www.cdc.gov/ print.do?url=http://www.cdc.gov/vaccines/vpd-vac/mening/vac-meningfs.htm (accessed August 28, 2011).
8. L. H. Harrison, C. L. Trotter, M. E. Ramsay, Global epidemiology of meningococcal disease. Vaccine 27 (suppl. 2), B51-B63 (2009).
9. O. O. Bilukha, N. Rosenstein; National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC), Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm. Rep. 54, 1-21 (2005).
10. J. MacNeil, Epidemiology of meningococcal disease in infants and young children. Advisory Committee on Immunization Practices. October 21 and 22, 2009. http://www.cdc.gov/vaccines/recs/ACIP/slides-oct09.htm#mv (accessed August 28, 2010).
11. Centers for Disease Control and Prevention (CDC), Active Bacterial Core Surveillance (ABCs) Report: Emerging Infections Program Network, Neisseria meningitidis, 1998-2008. http://www.cdc.gov/abcs/reports-findings/surv-reports. html (accessed August 28, 2011).
12. A. Sophian, J. Black, Prophylactic vaccination against epidemic meningitis. J. Am. Med. Assoc. LIX, 527-532 (1912).
13. H. W. Scherp, Studies on meningococcal infection XIII: Correlation between antipolysaccharide antibody and the antibody which protects mice against infection with type I meningococcus. J. Exp. Med. 81, 85-92 (1945).
14. P. Costantino, S. Viti, A. Podda, M. A. Velmonte, L. Nencioni, R. Rappuoli, Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine 10, 691-698 (1992).
15. C. L. Trotter, N. J. Andrews, E. B. Kaczmarski, E. Miller, M. E. Ramsay, Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364, 365-367 (2004).
16. M. M. Giuliani, J. Adu-Bobie, M. Comanducci, B. Aricò, S. Savino, L. Santini, B. Brunelli, S. Bambini, A. Biolchi, B. Capecchi, E. Cartocci, L. Ciucchi, F. Di Marcello, F. Ferlicca, B. Galli, E. Luzzi, V. Masignani, D. Serruto, D. Veggi, M. Contorni, M. Morandi, A. Bartalesi, V. Cinotti, D. Mannucci, F. Titta, E. Ovidi, J. A. Welsch, D. Granoff, R. Rappuoli, M. Pizza, A universal vaccine for serogroup B meningococcus. Proc. Natl. Acad. Sci. U.S.A. 103, 10834-10839 (2006).
17. J. Donnelly, D. Medini, G. Boccadifuoco, A. Biolchi, J. Ward, C. Frasch, E. R. Moxon, M. Stella, M. Comanducci, S. Bambini, A. Muzzi, W. Andrews, J. Chen, G. Santos, L. Santini, P. Boucher, D. Serruto, M. Pizza, R. Rappuoli, M. M. Giuliani, Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc. Natl. Acad. Sci. U.S.A. 107, 19490-19495 (2010).
18. L. Jódar, F. M. LaForce, C. Ceccarini, T. Aguado, D. M. Granoff, Meningococcal conjugate vaccine for Africa: A model for development of new vaccines for the poorest countries. Lancet 361, 1902-1904 (2003).
19. L. H. Harrison, C. L. Trotter, M. E. Ramsay, Global epidemiology of meningococcal disease. Vaccine 27 (suppl. 2), B51-B63 (2009).